NASDAQ:INAB IN8bio (INAB) Stock Price, News & Analysis $0.84 +0.03 (+3.71%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.81▼$0.8650-Day Range$0.80▼$1.6852-Week Range$0.65▼$2.48Volume54,027 shsAverage Volume337,795 shsMarket Capitalization$37.02 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get IN8bio alerts: Email Address IN8bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,091.9% Upside$10.00 Price TargetShort InterestHealthy1.53% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.44Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.60) to ($0.57) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.48 out of 5 starsMedical Sector305th out of 936 stocksBiological Products, Except Diagnostic Industry41st out of 154 stocks 3.5 Analyst's Opinion Consensus RatingIN8bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageIN8bio has only been the subject of 1 research reports in the past 90 days.Read more about IN8bio's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.53% of the float of IN8bio has been sold short.Short Interest Ratio / Days to CoverIN8bio has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in IN8bio has recently decreased by 39.52%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldIN8bio does not currently pay a dividend.Dividend GrowthIN8bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for INAB. Previous Next 3.0 News and Social Media Coverage News SentimentIN8bio has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for IN8bio this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for INAB on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added IN8bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IN8bio insiders have not sold or bought any company stock.Percentage Held by Insiders15.50% of the stock of IN8bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions92.05% of the stock of IN8bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about IN8bio's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for IN8bio are expected to grow in the coming year, from ($0.60) to ($0.57) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IN8bio is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IN8bio is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIN8bio has a P/B Ratio of 1.45. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about IN8bio's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIHow a $0.25 cent option contract makes my top traders feelIf you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…Click now to see for yourself what $0.25 Cent Trades is all about About IN8bio Stock (NASDAQ:INAB)IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.Read More INAB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INAB Stock News HeadlinesJune 24, 2024 | globenewswire.comIN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual ConferenceJune 13, 2024 | globenewswire.comIN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100July 26, 2024 | MarketBeat (Ad)We just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.June 3, 2024 | globenewswire.comIN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual MeetingMay 24, 2024 | globenewswire.comIN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024May 23, 2024 | globenewswire.comIN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual MeetingMay 20, 2024 | finance.yahoo.comINAB: 1Q:24 ResultsMay 14, 2024 | globenewswire.comIN8bio Announces Upcoming Presentation at 2024 European Hematology Association CongressJuly 26, 2024 | MarketBeat (Ad)We just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.May 13, 2024 | globenewswire.comIN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024May 10, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for IN8bio Amid Promising Clinical Trials and Strong PipelineMay 10, 2024 | msn.comIN8bio GAAP EPS of -$0.20 misses by $0.03May 10, 2024 | investorplace.comINAB Stock Earnings: IN8bio Misses EPS for Q1 2024May 9, 2024 | globenewswire.comIN8bio Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsApril 30, 2024 | globenewswire.comIN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed GlioblastomaApril 24, 2024 | globenewswire.comIN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual MeetingApril 22, 2024 | finance.yahoo.comINAB: Initiating Coverage – Enhancing the Insurgents of the Immune SystemApril 16, 2024 | globenewswire.comIN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity ConferenceSee More Headlines Receive INAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IN8bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:INAB CUSIPN/A CIK1740279 Webwww.in8bio.com Phone646-600-6438FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$12.50 Low Stock Price Target$7.50 Potential Upside/Downside+1,091.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,010,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-151.40% Return on Assets-107.81% Debt Debt-to-Equity Ratio0.02 Current Ratio4.10 Quick Ratio4.10 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.58 per share Price / Book1.45Miscellaneous Outstanding Shares44,124,000Free Float37,285,000Market Cap$37.02 million OptionableNot Optionable Beta0.06 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Tai-Wei Ho (Age 47)Co-Founder, President, CEO & Director Comp: $837kDr. Kate Rochlin Ph.D. (Age 43)Chief Operating Officer Comp: $565.4kDr. Trishna Goswami M.D. (Age 46)Chief Medical Officer Comp: $638.51kDr. Lawrence S. Lamb Ph.D. (Age 70)Executive VP, Co-Founder & Chief Scientific Officer Comp: $482.47kMr. Patrick McCall CPA (Age 41)CFO & Secretary Comp: $519.35kMr. Michael McNamaraVice President of AccountingMore ExecutivesKey CompetitorsT2 BiosystemsNASDAQ:TTOOOrphazyme A/SNASDAQ:ORPHEnlivex TherapeuticsNASDAQ:ENLVLantern PharmaNASDAQ:LTRNHCW BiologicsNASDAQ:HCWBView All CompetitorsInsidersJeremy R GraffBought 2,500 shares on 9/13/2023Total: $2,375.00 ($0.95/share)Patrick MccallBought 1,000 shares on 8/25/2023Total: $1,030.00 ($1.03/share)William Tai-Wei HoBought 23,800 shares on 8/24/2023Total: $24,990.00 ($1.05/share)View All Insider Transactions INAB Stock Analysis - Frequently Asked Questions How have INAB shares performed this year? IN8bio's stock was trading at $1.38 at the beginning of 2024. Since then, INAB stock has decreased by 39.2% and is now trading at $0.8390. View the best growth stocks for 2024 here. How were IN8bio's earnings last quarter? IN8bio, Inc. (NASDAQ:INAB) announced its earnings results on Thursday, May, 9th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.17) by $0.03. When did IN8bio IPO? IN8bio (INAB) raised $44 million in an initial public offering (IPO) on Friday, July 30th 2021. The company issued 4,000,000 shares at $10.00-$12.00 per share. B. Riley Securities acted as the underwriter for the IPO. How do I buy shares of IN8bio? Shares of INAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:INAB) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IN8bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IN8bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INAB Stock Alerts